Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens
New York, Jan 12, 2026, 14:44 ET — Regular session underway Nuvation Bio Inc shares tumbled almost 18% on Monday following news of a licensing deal with Japan’s Eisai and initial sales data for its lung-cancer treatment. The stock slipped 17.7% to $6.62, after fluctuating between $8.34 and $6.32 on roughly 11.4 million shares traded. (SEC) This is crucial now…